

**11-TTAG-032**

<b>Company Name</b>	Dermatex, LLC
<b>NAICS</b>	541712
<b>Address</b>	535 W. Research Center BLVD Suite 135
<b>City</b>	Fayetteville
<b>State</b>	AR
<b>ZIP</b>	72701
<b>County</b>	Washington
<b>Number of Employees</b>	13
<b>Year Established</b>	2008
<b>Company Web Site</b>	<a href="#">Client Company of Virtual Incubation</a>
<b>Contact Person</b>	Calvin Goforth
<b>Title</b>	President
<b>Phone</b>	479-571-2592
<b>Email Address</b>	<a href="mailto:calvin.goforth@virtual-incubation.com">calvin.goforth@virtual-incubation.com</a>
<b>Fax</b>	479-571-8814
<b>Secondary Contact Name</b>	Mark Kidd
<b>Secondary Contact Title</b>	VP of Finance and Admin
<b>Secondary Contact Phone</b>	479-571-2592
<b>Secondary Contact Email</b>	<a href="mailto:mkidd@virtual-incubation.com">mkidd@virtual-incubation.com</a>
<b>Resource Provider</b>	Dermatex, LLC
<b>RP Address</b>	535 W. Research Center BLVD Suite 135
<b>RP City</b>	Fayetteville
<b>RP State</b>	AR
<b>RP ZIP</b>	72701
<b>RP County</b>	Washington

<b>RP Project Contact</b>	Mark Kidd
<b>RP Title</b>	VP Finance and Admin
<b>RP Phone</b>	479-571-2592
<b>RP Email</b>	<a href="mailto:mkidd@virtual-incubation.com">mkidd@virtual-incubation.com</a>
<b>RP Fax</b>	479-571-8814
<b>Project Area</b>	<a href="#">Biotechnology, Bioengineering, Agriculture and Life Sciences - 17 - Other Medical Biotechnologies (Please provide short description in box provided below)</a>
<b>Project Area Brief Description</b>	The ultimate goal of this project is to develop a commercially viable, noninvasive method for discrimination of benign and dysplastic melanocytic skin lesions from malignant melanoma (MoleFraxTM)
<b>Federal Agency</b>	<a href="#">U.S. Department of Health and Human Services</a>
<b>Project Title</b>	11-TTAG-032 - MoleFrax
<b>Competitive Challenges</b>	DermaTex was created to commercialize a surface texture analysis based lesion analysis technology to differentiate benign lesions such as moles (benign and dysplastic nevi) or liver spots (lentigenes solaris), from malignant ones, such as lentigenes maligna and melanoma. Melanoma is a deadly cancer for which early diagnosis is key to survival. The company is developing a low cost, non-invasive, and objective aid in melanoma diagnosis.
<b>Specific Problem</b>	NIH SBIR Ph II The ultimate goal of this project is to develop a commercially viable, noninvasive method for discrimination of benign and dysplastic melanocytic skin lesions from malignant melanoma (MoleFraxTM).
<b>Solution</b>	If successful, this technology will reduce the cost, patient discomfort, and subsequent scarring that results from the surgical excision that is necessary for histopathological examination.
<b>Implementation Plan</b>	To improve specificity, the method of taking the impressions will be improved, several different measurement instruments will be evaluated to select the best for discrimination, new characterization methods will tested, and new discrimination criteria will be developed. The hypothesis is that degree of the success of the method depends in part on the accuracy and detail in the measurement, which depends on the fidelity of the impression and the quality of the measurement instrument in the applicable scale range. The appropriate characterization of the texture measurement is essential. The current hypothesis is that the malignancy reduces the complexity of the surface of the lesion and the surrounding skin over a certain range of scale, which we have

	characterized using the area-scale fractal complexity. More scale-sensitive texture characterization parameters will be tested on a greater number of impressions to find new criteria to increase specificity. An impression kit will be developed so that clinicians can return the impressions to a central lab for measurement and analysis. Clinical studies or trials will be performed.
<b>Maintenance Plan</b>	Dermatex, LLC will maintain the solution by obtaining any federal regularity. Also, partnering with services to further the research. We will also seek investment funding.
<b>Step 1</b>	Preparatory Work: - Define research objectives - Outline Proposal - Discussions with funding agency - Literature search and review - Identification of potential users and partners
<b>Step 1 Time</b>	20.00
<b>Step 1 Budget</b>	\$1,000
<b>Step 2</b>	proposal content development - Technology description -work plan development - budget development - commercialization plan
<b>Step 2 Time</b>	50.00
<b>Step 2 Budget</b>	\$2,500
<b>Step 3</b>	Final Report Preparation - Proposal review - formatting and proofreading - letters of support, consultant letters - agency forms - cover letters, copies, mailing
<b>Step 3 Time</b>	30.00
<b>Step 3 Budget</b>	\$1,500
<b>Increased Sales</b>	\$0
<b>Retained Sales</b>	\$0
<b>CS Inventory</b>	\$0
<b>CS Labor</b>	\$0
<b>CS Materials</b>	\$0
<b>CS Other</b>	\$0
<b>II Plant</b>	\$0
<b>II IS</b>	\$0
<b>II Workforce</b>	\$0

<b>II Research</b>	\$250,000
<b>II Other</b>	\$0
<b>AUI</b>	\$0
<b>SOI</b>	\$0
<b>Job Retention</b>	0
<b>Job Creation</b>	1
<b>YN 90Days</b>	No
<b>YN Affiliation</b>	Yes
<b>YN Agreement</b>	Yes
<b>YN Total Project Price</b>	Yes
<b>Explain Total Project Price</b>	
<b>YN Cash Match Agreement</b>	Yes
<b>Copied</b>	No
<b>TTAG ID</b>	11-TTAG-032
<b>Signature Panel - RP AR Name</b>	Mark Kidd
<b>Signature Panel - RP AR Email</b>	<a href="mailto:mkidd@virtual-incubation.com">mkidd@virtual-incubation.com</a>
<b>Signature Panel - Enterprise AR Name</b>	Calvin Goforth
<b>Enterprise - Email</b>	.....
<b>Signature Panel - Enterprise AR Email</b>	<a href="mailto:calvin.goforth@virtual-incubation.com">calvin.goforth@virtual-incubation.com</a>
<b>Include in Batch</b>	Yes
<b>Batch Number</b>	NA
<b>Application Status</b>	Pending
<b>Organization</b>	ASTA
<b>BatchTest</b>	Processed
<b>Batch Date</b>	
<b>Set Batch Number</b>	

<b>Lvl4</b>	No
<b>Application Description</b>	8-Biotechnology, Bioengineering & Life Sciences
<b>SBIR-STTR</b>	Yes